Physician profile
Mariah Holmes
NPI 1699474270
$2,278.07
in general payments reported to CMS, 2019-2025
33 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.41 · 2024: $376 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.09 |
| Education | $397.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $252.78 | 2025 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $222.05 | 2024-2025 | Lynparza, Tagrisso, Airsupra |
| Seagen INC. | $174.99 | 2025 | |
| Incyte Corporation | $146.51 | 2025 | Monjuvi, Jakafi, Pemazyre |
| Abbvie INC. | $137.98 | 2023-2025 | |
| Lilly USA, LLC | $118.38 | 2024-2025 | Zepbound, Mounjaro, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $109.71 | 2025 | Fruzaqla, Ninlaro, Iclusig |
| Gilead Sciences, INC. | $97.03 | 2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $93.73 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.92 | 2025 | |
| Amgen INC. | $85.57 | 2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $74.34 | 2024-2025 | Trelegy Ellipta, Arexvy, Ojjaara |
| Merck Sharp & Dohme LLC | $65.39 | 2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $59.47 | 2025 | |
| Astellas Pharma US INC | $59.21 | 2024-2025 | Veozah, Xtandi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45.86 | 2025 | |
| Genentech USA, INC. | $45.51 | 2025 | Lunsumio, Polivy |
| E.R. Squibb & Sons, L.L.C. | $43.90 | 2025 | Opdivo, Opdualag |
| Genmab U.S., INC. | $42.57 | 2025 | Tivdak, Epkinly |
| Novo Nordisk INC | $38.97 | 2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $29.81 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $27.86 | 2025 | Ultomiris |
| Array Biopharma INC | $27.67 | 2025 | Mektovi, Braftovi, Lorbrena |
| Agios Pharmaceuticals, INC. | $23.94 | 2025 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2025 | |
| Celgene Corporation | $21.62 | 2025 | Reblozyl |
| Puma Biotechnology, INC. | $21.35 | 2025 | |
| Blue Earth Diagnostics | $19.77 | 2025 | Posluma |
| Celltrion USA INC. | $19.29 | 2025 | Vegzelma |
| Caris Mpi, INC. | $17.14 | 2025 | Mi Cancer Seek |
| Eisai INC. | $17.07 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.39 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $13.51 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.